Herombopag ( DrugBank: - )
2 diseases
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
60 | Aplastic anemia | 1 |
63 | Idiopathic thrombocytopenic purpura | 1 |
60. Aplastic anemia
Clinical trials : 245 / Drugs : 318 - (DrugBank : 86) / Drug target genes : 44 - Drug target pathways : 166
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05660785 (ClinicalTrials.gov) | December 1, 2022 | 23/11/2022 | Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia | The Efficacy and Safety of Herombopag Combined With Cyclosporine for Patients With Non Severe Aplastic Anemia | Non Severe Aplastic Anemia;Untreated | Drug: Herombopag | Institute of Hematology & Blood Diseases Hospital | Jiangsu Hengrui Pharmaceuticals Co.,Ltd | Recruiting | 18 Years | N/A | All | 54 | Phase 2 | China |
63. Idiopathic thrombocytopenic purpura
Clinical trials : 391 / Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05685420 (ClinicalTrials.gov) | January 23, 2023 | 6/1/2023 | Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia | Extension Study of Herombopag in Children and Adolescents With Chronic Primary Immune Thrombocytopenia | Immune Thrombocytopenia | Drug: Herombopag | Jiangsu HengRui Medicine Co., Ltd. | NULL | Not yet recruiting | 6 Years | 17 Years | All | 117 | Phase 3 | NULL |